HOXA9 and leukemia: Recently, Heikamp and colleagues demonstrated that mouse leukemia cell lines driven by NUP98-HOXA9 and NUP98-JARID1A fusion oncoproteins are sensitive to the menin-MLL1 inhibitor VTP50469 by significantly increasing the OS of mice engrafted with cells from leukemia patients with genetic rearrangements above [111].